| Name | Title | Contact Details |
|---|
Express Medical Transporters is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CompManagement Health Systems, Inc. is a Dublin, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
With more than 30 years of experience marketing to healthcare professionals, patients, and consumers, FCB Health produces work that is both strategically relevant and creatively compelling. We provide clients with multichannel capabilities, including payer strategy and marketing, professional education, video production, strategic planning, and media services.
Established in 1988, Health Design Plus (HDP) initially a Care Management company, expanded its suite of services to include network development/management and claims administration. With over 25 years of continued success, Health Design Plus continues to offer new products, such as Good Health by Design®, a suite of Wellness programs including LifeStart®, a Maternity Management program, Wellness Counts®, a biometric screening and coaching program, Carewise®, a Care Management program, and Healthy Living™, a Disease Management program, designed to fit all wellness-readiness levels, promoting healthier lifestyle choices and behavior modification to reach personal goals. Health Design Plus helps clients fuel their fiscal health in the marketplace while improving the health of their employees and members. Recently, HDP has gained national recognition as the industry leader in Domestic Travel Surgery programs with the launch of CliniFIT™ Centers of Excellence. HDP`s CliniFIT™ Centers of Excellence programs offer employers unparalleled commitment to consistently deliver safe, effective, evidence-based care. Qualified employees have access to recognized leaders in specific fields of medicine, Cardiac, Spine and Joint Replacement.
Enterin is pioneering the medical community`s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease. We are leveraging years of research to become the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease. Our lead compound, ENT-01 (also known as kenterin), displaces membrane-bound alpha- synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson`s disease. In the gut, this results in improved motility. We are now progressing this drug through clinical trials in an attempt to reverse the constipation of Parkinson`s disease. Our long-term mission is to become the world leader in developing pharmaceutical therapies that repair the gut-brain axis.